Table of contents
August 2007 Vol 7 No 8
Research Highlights
Microenvironment: A disturbed background | PDF (307 KB)
p566 | doi:10.1038/nrc2194
Genetics: Common ground | PDF (180 KB)
p567 | doi:10.1038/nrc2195
In the news
FDA squashes tomato anticancer claims | PDF (66 KB)
p567 | doi:10.1038/nrc2207
Breast cancer: X-linked tumour suppression | PDF (167 KB)
p568 | doi:10.1038/nrc2200
Signalling: Expression levels are not as they appear | PDF (219 KB)
p568 | doi:10.1038/nrc2201
Tumorigenesis: Innate response | PDF (138 KB)
p568 | doi:10.1038/nrc2206
Trial Watch
| PDF (78 KB)
p569 | doi:10.1038/nrc2204
Breast cancer: A useful combination | PDF (115 KB)
p570 | doi:10.1038/nrc2197
Targeting: Intra-fering with interactions | PDF (157 KB)
p570 | doi:10.1038/nrc2198
Angiogenesis: Hidden signatures written in blood | PDF (126 KB)
p571 | doi:10.1038/nrc2199
Immune tolerance: New mechanism of tolerance induction in cancer | PDF (147 KB)
p572 | doi:10.1038/nrc2202
In brief
| PDF (90 KB)
p572 | doi:10.1038/nrc2205
Reviews
See also: Correspondence by Cavaletti | Correspondence by Kelland
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
p573 | doi:10.1038/nrc2167
Cisplatin was first used for cancer therapy in the 1970s. Interest in platinum drugs has been revived recently: new agents have been developed, a better understanding of resistance mechanisms has been gained, and combination trials with resistance modulators and targeted agents have been initiated.
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima, Constantine Mitsiades, Giovanni Tonon, Paul G. Richardson & Kenneth C. Anderson
p585 | doi:10.1038/nrc2189
Multiple myeloma is an incurable B-cell malignancy that is actively sustained by the bone marrow microenvironment. Targeting myeloma cells and their bone marrow interactions seems a promising strategy to overcome drug resistance and improve patient outcome.
Molecular mechanisms of alcohol-mediated carcinogenesis
Helmut K. Seitz & Felix Stickel
p599 | doi:10.1038/nrc2191
Alcohol is one of the most widely consumed toxic substances, and approxmiately 3.6% of cancers result from chronic alcohol drinking. What are some of the mechanisms by which alcohol acts as a carcinogen?
Perspectives
Innovation
Active-site directed probes to report enzymatic action in the ubiquitin proteasome system
Huib Ovaa
p613 | doi:10.1038/nrc2128
Irreversible covalent inhibitors equipped with reporter groups allow the study of target enzymes based on catalytic activity instead of expression level. This Perspective discusses the design and use of such probes directed at the ubiquitin–proteasome system. Can they identify new cancer therapies that target this system?
Opinion
Treating prostate cancer: a rationale for targeting local oestrogens
Stuart J. Ellem & Gail P. Risbridger
p621 | doi:10.1038/nrc2174
A role for oestrogen has been implicated in the development of prostate cancer, but this role is complex. Should selective oestrogen-receptor modulators in conjunction with contemporary androgen-ablation therapy be used to treat this disease?
Opinion
The disappearing Barr body in breast and ovarian cancers
Gayle J. Pageau, Lisa L. Hall, Shridar Ganesan, David M. Livingston & Jeanne B. Lawrence
p628 | doi:10.1038/nrc2172
This article examines whether heterochromatic instability might explain the loss of the heterochromatic inactive X chromosome (Barr body) in some breast and ovarian cancers. Might this mechanism have wider implications for the evolution of some cancer types?